Does metformin actually slow aging?

Does metformin slow aging?

No completed human trial has shown that it does. The evidence for metformin as an anti-aging drug stops at animal studies and an observational pattern in people who already have diabetes. The TAME trial, the study specifically designed to test the claim in healthy older adults, has been proposed for more than a decade and has not enrolled a single person. What is actually proven about metformin and aging is narrower, and more useful, than what the longevity crowd implies.

Why longevity influencers are obsessed with a cheap diabetes pill

Metformin is a six decade old, off patent, inexpensive medication approved for type 2 diabetes and for reducing diabetes risk in people with prediabetes. In the longevity world, from biohacker supplement stacks to forums built around extending healthspan, it gets treated as a staple alongside rapamycin and NMN. Part of the appeal is the price and the long record of human safety data. Part of it is a genuine scientific hypothesis: metformin activates a cellular energy sensor called AMPK and dampens a growth pathway called mTOR, both of which are tied to how cells age in lab models. That is a real, testable biological idea. It is not, on its own, proof that the drug slows aging in a living person, and the gap between a plausible mechanism and a proven outcome is exactly where this topic gets oversold.

What the monkey study actually found

The strongest recent evidence comes from a 2024 study in the journal Cell, led by researchers at the Chinese Academy of Sciences. The team gave daily metformin to a small group of elderly male macaque monkeys for 40 months and compared them with untreated monkeys of the same age and with younger monkeys. The treated monkeys' brains measured about six years younger than untreated monkeys of the same age, based on imaging driven aging clocks, with the clearest effect in the frontal lobe. The researchers also reported slower aging signals in the liver, kidney and skin of the treated animals.

Outside researchers were cautiously impressed, not convinced. Alex Soukas, a molecular geneticist at Massachusetts General Hospital, called it "the most quantitative, thorough examination of metformin action that I've seen beyond mice." Rafael de Cabo, a translational geroscientist at the National Institute on Aging, pointed to the limits of the same study: only a handful of monkeys received the drug, no females were included, and the researchers never tracked whether the treated animals actually lived longer, only whether they measured younger on specific biological tests. Small, short, male only primate studies are informative, not definitive.

The human evidence is a different, weaker kind of proof

In people, the case for metformin and aging rests mostly on one pattern: among people who already have type 2 diabetes, several reviews, including one published in 2017, found that metformin users have lower all cause mortality than diabetics taking other medications. That association is worth taking seriously, but it is an observational pattern inside a population that already has a disease, not a controlled trial in healthy people. It does not answer what metformin does for someone who does not have diabetes, which is the actual question most longevity users are asking. On that narrower question the evidence thins out further, since reviews have not found that metformin meaningfully reduces cancer or cardiovascular risk in people who do not have diabetes to begin with.

Two researchers interviewed by Medical News Today summed up the gap plainly. David Cutler, a physician, said "the evidence is not yet strong enough to say that metformin extends human life span." Diogo Barardo, a researcher who studies aging biomarkers, put it even more directly: "changing a pathway involved in aging is not the same as proving that a treatment slows aging in a person."

Why the TAME trial still has not happened

The study that could settle this is called TAME, Targeting Aging with Metformin. Researchers working with the American Federation for Aging Research designed it to randomize 3,000 adults aged 65 to 79, without diabetes, to either metformin or a placebo for about four years, tracking a combined measure of age related disease and death as the main outcome. It is a serious, well designed trial, built with FDA input on how its endpoints would need to look to support a future aging indication. It is also, as of this writing, a trial that exists only on paper. More than ten years after it was first proposed, TAME has not secured full funding and has not enrolled a single participant, largely because no company has a strong financial incentive to fund a trial for a cheap, generic drug nobody can patent. That single fact is the clearest signal of where the science actually stands: if the proof already existed, there would be nothing left for TAME to test.

This is the same evidentiary gap that runs across most of the longevity supplement aisle. NMN and rapamycin both have real biology behind them and no completed human trial proving either one extends lifespan. Metformin is arguably the most plausible of the three, since it already carries decades of human safety data from diabetes care, but plausible is still not the same claim as proven.

Is it worth taking anyway?

Metformin is not a supplement available over the counter. It requires a prescription, and doctors can legally prescribe it off label, which some longevity focused physicians do for patients who want it. Off label is a legal category, though, not an evidence-based one. The drug has real side effects: nausea, diarrhea and stomach upset are common when starting it, and long-term use can lower vitamin B12 levels, which matters for nerve and blood health, especially in older adults. Rare cases of lactic acidosis, a serious buildup of acid in the blood, have occurred mostly in people with kidney problems, who are generally advised not to take the drug at all. None of this makes metformin dangerous for its approved use in diabetes, where its safety record over decades is strong. It does mean that taking it purely as a hoped-for aging treatment means accepting known, real risks in exchange for a benefit that nobody has actually demonstrated in a healthy person yet.

Our take

Metformin is probably the most scientifically plausible item in the biohacker longevity cabinet, better supported by decades of human use than most supplements sold on the same premise. But plausible and proven are different claims, and the distance between them is the entire reason TAME was designed in the first place. Until that trial, or one like it, actually runs to completion, the honest answer to whether metformin slows aging is: maybe, in a way nobody has tested in a healthy person yet. Anyone seriously considering it should talk to a doctor who knows their kidney function and full medication list, not a podcast or a supplement stack spreadsheet.

This is general information, not medical advice. Talk to a clinician before changing anything, especially if you are pregnant, nursing, or managing a condition.